Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects
Molecular Psychiatry October 15, 2013 Gerard Sanacora, Mark A. Smith, Sanjeev Pathak et al. 234 citations
NMDA channel blockers can produce antidepressant effects without the psychotomimetic and dissociative side effects seen with ketamine. Using quantitative electroencephalography to align doses of a low-trapping NMDA channel blocker, AZD6765 (lanicemine), to ketamine, the antidepressant response was maintained with repeated and intermittent drug administration in placebo-controlled data. This provides a path for developing glutamatergic-based treatments for treatment-refractory mood disorders.